Cargando…

O(6)-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms

BACKGROUND: Streptozocin (STZ) is used for treating both pancreatic (PanNET) and gastrointestinal (GI-NET) neuroendocrine tumors but its therapeutic efficacy is relatively low in GI-NETs. Therefore, it has become pivotal to select GI-NET patients who could benefit from STZ treatment. STZ is transpor...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Hirofumi, Yamazaki, Yuto, Fujishima, Fumiyoshi, Izumi, Komoto, Imamura, Masayuki, Hijioka, Susumu, Toriyama, Kazuhiro, Yatabe, Yasushi, Kudo, Atsushi, Motoi, Fuyuhiko, Unno, Michiaki, Sasano, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720403/
https://www.ncbi.nlm.nih.gov/pubmed/33287738
http://dx.doi.org/10.1186/s12885-020-07579-6
_version_ 1783619844539678720
author Watanabe, Hirofumi
Yamazaki, Yuto
Fujishima, Fumiyoshi
Izumi, Komoto
Imamura, Masayuki
Hijioka, Susumu
Toriyama, Kazuhiro
Yatabe, Yasushi
Kudo, Atsushi
Motoi, Fuyuhiko
Unno, Michiaki
Sasano, Hironobu
author_facet Watanabe, Hirofumi
Yamazaki, Yuto
Fujishima, Fumiyoshi
Izumi, Komoto
Imamura, Masayuki
Hijioka, Susumu
Toriyama, Kazuhiro
Yatabe, Yasushi
Kudo, Atsushi
Motoi, Fuyuhiko
Unno, Michiaki
Sasano, Hironobu
author_sort Watanabe, Hirofumi
collection PubMed
description BACKGROUND: Streptozocin (STZ) is used for treating both pancreatic (PanNET) and gastrointestinal (GI-NET) neuroendocrine tumors but its therapeutic efficacy is relatively low in GI-NETs. Therefore, it has become pivotal to select GI-NET patients who could benefit from STZ treatment. STZ is transported via the glucose transporter 2 (GLUT2) into the cells and the loss of O6-methylguanine DNA methyltransferase (MGMT) also increases its therapeutic efficacy. Therefore, GLUT2 high and MGMT low status could be the surrogate markers of STZ. METHODS: In this study, we examined the MGMT and GLUT2 status in gastrointestinal neuroendocrine neoplasm (NEN). We studied 84 NEN cases: 33 foregut and 37 hindgut GI-NETs and 14 gastrointestinal neuroendocrine carcinomas (GI-NECs). RESULTS: In GI-NETs, MGMT scores of ≥2 and ≥ 3 were 77% (54/70) and 56% (39/70), respectively, and GLUT2 scores of ≥4 and ≥ 6 were 30% (21/70) and 4.3% (3/70), respectively. Methylation-specific polymerase chain reaction revealed that MGMT promoter methylation was detected only in 2/14 GI-NECs but none of the included GI-NETs. GLUT2 (GLUT2 score) and MGMT immunoreactivity (MGMT and H-scores) were both significantly correlated with Ki-67 labeling index (GLUT2 score: P = 0.0045, ρ = − 0.4570; MGMT score: P = 0.0064, ρ = − 0.4399; H-score: P = 0.0110, ρ = − 0.4135) and MGMT immunoreactivity were significantly correlated with GLUT2 immunoreactivity (MGMT score: P = 0.0198; H-score, P = 0.0004, ρ = 0.5483) in hindgut NETs, but not in foregut NETs. However, discrepancies from the above correlation between GLUT2 and MGMT immunoreactivity were detected in several GI-NET cases which could be potential candidates for STZ therapy. CONCLUSION: The evaluation of MGMT and GLUT2 status could provide an important information in planning STZ therapy in GI-NET patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-020-07579-6.
format Online
Article
Text
id pubmed-7720403
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77204032020-12-07 O(6)-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms Watanabe, Hirofumi Yamazaki, Yuto Fujishima, Fumiyoshi Izumi, Komoto Imamura, Masayuki Hijioka, Susumu Toriyama, Kazuhiro Yatabe, Yasushi Kudo, Atsushi Motoi, Fuyuhiko Unno, Michiaki Sasano, Hironobu BMC Cancer Research Article BACKGROUND: Streptozocin (STZ) is used for treating both pancreatic (PanNET) and gastrointestinal (GI-NET) neuroendocrine tumors but its therapeutic efficacy is relatively low in GI-NETs. Therefore, it has become pivotal to select GI-NET patients who could benefit from STZ treatment. STZ is transported via the glucose transporter 2 (GLUT2) into the cells and the loss of O6-methylguanine DNA methyltransferase (MGMT) also increases its therapeutic efficacy. Therefore, GLUT2 high and MGMT low status could be the surrogate markers of STZ. METHODS: In this study, we examined the MGMT and GLUT2 status in gastrointestinal neuroendocrine neoplasm (NEN). We studied 84 NEN cases: 33 foregut and 37 hindgut GI-NETs and 14 gastrointestinal neuroendocrine carcinomas (GI-NECs). RESULTS: In GI-NETs, MGMT scores of ≥2 and ≥ 3 were 77% (54/70) and 56% (39/70), respectively, and GLUT2 scores of ≥4 and ≥ 6 were 30% (21/70) and 4.3% (3/70), respectively. Methylation-specific polymerase chain reaction revealed that MGMT promoter methylation was detected only in 2/14 GI-NECs but none of the included GI-NETs. GLUT2 (GLUT2 score) and MGMT immunoreactivity (MGMT and H-scores) were both significantly correlated with Ki-67 labeling index (GLUT2 score: P = 0.0045, ρ = − 0.4570; MGMT score: P = 0.0064, ρ = − 0.4399; H-score: P = 0.0110, ρ = − 0.4135) and MGMT immunoreactivity were significantly correlated with GLUT2 immunoreactivity (MGMT score: P = 0.0198; H-score, P = 0.0004, ρ = 0.5483) in hindgut NETs, but not in foregut NETs. However, discrepancies from the above correlation between GLUT2 and MGMT immunoreactivity were detected in several GI-NET cases which could be potential candidates for STZ therapy. CONCLUSION: The evaluation of MGMT and GLUT2 status could provide an important information in planning STZ therapy in GI-NET patients. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-020-07579-6. BioMed Central 2020-12-07 /pmc/articles/PMC7720403/ /pubmed/33287738 http://dx.doi.org/10.1186/s12885-020-07579-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Watanabe, Hirofumi
Yamazaki, Yuto
Fujishima, Fumiyoshi
Izumi, Komoto
Imamura, Masayuki
Hijioka, Susumu
Toriyama, Kazuhiro
Yatabe, Yasushi
Kudo, Atsushi
Motoi, Fuyuhiko
Unno, Michiaki
Sasano, Hironobu
O(6)-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms
title O(6)-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms
title_full O(6)-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms
title_fullStr O(6)-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms
title_full_unstemmed O(6)-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms
title_short O(6)-methylguanine DNA methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms
title_sort o(6)-methylguanine dna methyltransferase and glucose transporter 2 in foregut and hindgut gastrointestinal neuroendocrine neoplasms
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720403/
https://www.ncbi.nlm.nih.gov/pubmed/33287738
http://dx.doi.org/10.1186/s12885-020-07579-6
work_keys_str_mv AT watanabehirofumi o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT yamazakiyuto o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT fujishimafumiyoshi o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT izumikomoto o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT imamuramasayuki o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT hijiokasusumu o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT toriyamakazuhiro o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT yatabeyasushi o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT kudoatsushi o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT motoifuyuhiko o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT unnomichiaki o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms
AT sasanohironobu o6methylguaninednamethyltransferaseandglucosetransporter2inforegutandhindgutgastrointestinalneuroendocrineneoplasms